Atracurium (besylate)

Atracurium (BW-33A) besylate is a potent, competitive and non-depolarizing neuromuscular blocking agent. Atracurium besylate also is an AChR receptor antagonist. Atracurium besylate induces bronchoconstriction and neuromuscular blockade. Atracurium besylate promotes astroglial differentiation[1][2][3][4][5].

Product Specifications

CAS Number

[64228-81-5]

Product Name Alternative

BW-33A

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

NAChR

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel; Neuronal Signaling

Applications

Neuroscience-Neuromodulation

Field of Research

Cancer; Inflammation/Immunology; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/Atracurium-besylate.html

Purity

99.13

Solubility

DMSO : 125 mg/mL (ultrasonic)

Smiles

O=S(C1=CC=CC=C1)([O-])=O.O=C(OCCCCCOC(CC[N+]2(C)C(CC3=CC=C(OC)C(OC)=C3)C4=C(C=C(OC)C(OC)=C4)CC2)=O)CC[N+]5(C)C(CC6=CC=C(OC)C(OC)=C6)C7=C(C=C(OC)C(OC)=C7)CC5.O=S(C8=CC=CC=C8)([O-])=O

Molecular Formula

C65H82N2O18S2

Molecular Weight

1243.48

Precautions

H302, H315, H319, H335

References & Citations

[1]Basta SJ, et al. Clinical pharmacology of atracurium besylate (BW 33A) : a new non-depolarizing muscle relaxant. Anesth Analg. 1982 Sep;61 (9) :723-9.|[2]Levitt RC, et al. Genetic susceptibility to atracurium-induced bronchoconstriction. Am J Respir Crit Care Med. 1995 May;151 (5) :1537-42.|[3]Mayer B, et al. Inflammatory liver disease shortens atracurium-induced neuromuscular blockade in rats. Eur J Anaesthesiol. 2001 Sep;18 (9) :599-604.|[4]Spina R, et al. Atracurium Besylate and other neuromuscular blocking agents promote astroglial differentiation and deplete glioblastoma stem cells. Oncotarget. 2016 Jan 5;7 (1) :459-72.|[5]Nascimento DC, et al. Cellular mechanisms of atracurium-induced tetanic fade in the isolated rat muscle. Basic Clin Pharmacol Toxicol. 2004 Jul;95 (1) :9-14.